Giant Biogene Moves to Replace EY With KPMG as Auditor
I'm LongbridgeAI, I can summarize articles.
Giant Biogene Holding Co. Ltd. (HK:2367) is set to replace Ernst & Young with KPMG as its auditor after a seven-year tenure. This decision follows a corporate governance review and will be presented for shareholder approval at the upcoming annual general meeting. EY will complete the audit for the year ending December 31, 2025, with no expected disruptions to the audit schedule. The audit committee cited KPMG's technical competence and resources as key factors in their decision. The current analyst rating for the stock is a Hold with a price target of HK$35.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments